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demand shows how consumers feel about a particular
product and its substitutes, thus having direct economical
impact on consumption.
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OBJECTIVE: To investigate the incremental cost-effec-
tiveness of ganciclovir relative to acyclovir in preventing
cytomegalovirus disease (CMV) after liver transplanta-
tion, using Bayesian methods. METHODS: Analysis was
based on 134 patients in a randomized clinical trial com-
paring oral acyclovir (ACV) to intravenous ganciclovir
followed by oral acyclovir (GCV). Probability of CMV,
ICU and non-ICU days and total billed charges were
modeled as interdependent binomial, poison and log-
transformed linear regressions of recipient, donor and
surgery covariates using Markov Chain Monte Carlo
(MCMC) with non-informative priors. RESULTS: The
posterior median (PM) attributable risk reduction for
CMV ranged from 16% (95% posterior range (PR): 5%–
22%) when both recipients and donors are previously ex-
posed to cytomegalovirus (R/D) to 29% (95%PR:
7%–43%) when recipients are not exposed, but donors
are (R/D). For average patients, CMV infection yields
a PM 3.5 ICU day increase (95%PR: 2.3–5.0) and a PM
1.9 non-ICU day increase (95%PR: .2–3.7). The associa-
tion of additional days with total charges is non-linear.
On average, increasing ICU-days from 4 to 5 yields a PM
increase in total billed charges of $3,692 (95%PR: $2,501–
$4,955), and increasing non-ICU days from 12 to 13
yields a PM increase of $1,311 (95%PR: $610–$2,052).
Independent of the impact on days, CMV yields a PM
$17,638 charge increase (95%PR $5,539–$31,220). The
average incremental cost-effectiveness for the study sample
is a 14.8% risk reduction and $12,048 savings. 73.1%
percent of the probability mass of the incremental cost-
effectiveness distribution lies in the “dominant quadrant”
(GCV reduces infections and total charges). For R/D
cases, GCV dominates ACV 93.5% of the time, and aver-
age incremental cost-effectiveness is a 27.1% risk reduc-
tion and $19,545 savings. CONCLUSION: The study
demonstrates cost-effectiveness of GCV relative to ACV
in prevention of CMV post transplant. The model explic-
itly associates covariates and treatment with cost-effec-
tiveness, reflecting uncertainty using a Bayesian frame-
work.
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Antibiotic misuse is a growing national concern. Sinusitis
is the leading indication for adult antibiotic outpatient
prescriptions. Physician prescribing behavior was care-
fully reviewed in treating sinusitis with approved antibi-
otic agents. METHODS: All subjects with pharmacy
claims for acute sinusitis (ICD9-CM code of 461) in the
year 1997 to 1998 from a 932,000 enrollee Midwest in-
surance company were included in the study. A logistic
regression model (N  12,765) was used to identify fac-
tors affecting the choice of antibiotic, with clarithromy-
cin prescription coded as “1” and any other antibiotic
prescription (amoxicillin, amoxicillin-clavulanate, eryth-
romycin, erythromycinsulfisox, loracarbef, cephalosporin,
azithromycin) coded as “0”. The independent variables
included in the model were age category (12–20, 21–40,
41–65, and 65 years or older), gender, success rate for
each antibiotic, incidence of second, third or fourth epi-
sode within the year, pre and intra-episode severity. RE-
SULTS: The mean age of subjects was 29.7 ( 17.8)
years. The prevalence rate of sinusitis was 12 cases per
1000, of which, 13 percent had two or more episodes of
sinusitis within a year. Patients with two episodes were
19 times more likely to get initial treatment with clarithro-
mycin than patients in first episode. The odds of treat-
ment initiation with clarithromycin were 27 percent
higher when age increased by one categorical unit. The
odds of treatment initiation with clarithromycin was 18
percent higher in women compared to men. CONCLU-
SION: The results indicated that clarithromycin is used
more often for treating sinusitis in patients who have
multiple episodes. Generalization of this analysis needs to
be confirmed using data from multiple managed care plans.
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OBJECTIVES: The clinical course of chronic bronchitis is
characterized by acute exacerbations (AECB), during which
